Calculation of Oral Morphine Equivalents (OME)

Overview

Oral Morphine Equivalents (OME) are approximations of the equianalgesic effects of other opioids compared to oral morphine. Thus, OMEs indicate how much of the reference drug oral morphine would be required to treat pain as effectively as the opioid morphine is compared with. This approach allows for the comparison of different opioid treatments for pain.

Opioid equivalence solely refers to analgesic potency, the ability to treat pain and does not allow for the direct comparison of risks of opioid-related adverse events such as sedation or respiratory depression. This becomes most obvious when looking at the equivalence factors for neuraxial (spinal and epidural) administration of opioids:  neuraxial administration of opioids reduces pain very effectively while being comparatively less likely to cause respiratory depression or sedation.

Other related abbreviations are morphine milligram equivalents (MMEs) and, when describing OME or MME per day, morphine equivalent daily dose (MEDD).

Purpose of Oral Morphine Equivalence (OME) calculations

  • OME calculations help identify opioid tolerance in individual patients. The FDA defines an opioid-tolerant patient as receiving for 1 week or longer at least 60 mg oral morphine/day or an equianalgesic dose of another opioid.
  • OME calculations facilitate monitoring changes in opioid utilization over time. For this reason, UCSF employs an OME calculator in the APEX Pain Summary. 
  • OME calculations are needed to identify the need for mandated naloxone prescriptions when opioids are prescribed.
  • OME calculation allows for the comparison of different opioids for research or for monitoring purposes.

Opioid Equivalence Factors used at UCSF​

OpioidRouteDose in commonly used UnitMultiplication Factor to get OMEOral Morphine Equivalents
AlfentanilIVmg3030mg
BuprenorphinePO/ SL/ buccal1mg3030mg
BuprenorphineIV/IM1mg100100mg
BuprenorphineTransdermal1 mcg/h751.8mg/d (75mcg/h)
Butorphanol IV/IM1mg1515mg
Butorphanol nasal1mg77mg
CodeinePO1 mg0.150.15mg
CodeineIV1 mg0.30.3mg
FentanylIV1 mcg300300 mcg/0.3mg
Fentanylbuccal/ lozenge1mcg1300.13mg
Fentanylfilm/ oral spray1mcg1800.18mg
Fentanylnasal spray1mcg1600.16mg
fentanylIntrathecal1mcg37503.75mg
FentanylEpidural1 mcg9000.9mg
FentanylTransdermal1 mcg/h1002.4mg/d (100mcg/h)
HydrocodonePO1 mg11mg
HydromorphoneIV1 mg1818mg
HydromorphonePO1 mg55mg
HydromorphoneIntrathecal1mcg5000.5mg
HydromorphoneEpidural1 mcg1000.1mg
HydromorphoneRectal1 mg44mg
LevorphanolIV1 mg1515mg
LevorphanolPO1 mg1111mg
MeperidineIV1 mg0.30.3mg
MeperidinePO1 mg0.10.1mg
MethadoneIV1mg66mg
MethadonePO1mg4.74.7mg
MorphineIV1 mg33mg
MorphineEpidural1 mg3030mg
MorphineIntrathecal1mg300300mg
MorphinePO1 mg11mg
MorphineRectal1 mg11mg
NalbuphineIV1 mg33mg
OpiumPO1mg11mg
OpiumRectal1mg11mg
OxycodonePO1 mg1.51.5mg
OxycodoneIV1 mg33mg
OxymorphonePO1 mg33mg
OxymorphoneIV1 mg3030mg
PentazocineIV1 mg0.51mg 
PropoxyphenePO1 mg0.150.15mg 
RemifentanilIV1mcg300300mcg/0.3mg
SufentanilIV1mcg30003mg
SufentanilEpidural1mcg53105,31mg
TapentadolPO1 mg0.40.4mg
TramadolPO1 mg0.20.2mg
TramadolIV1 mg0.30.3mg

References

  1. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiology and Drug Safety 2016; 25(6): 733-7